ArticleOncogene2016
Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer.
Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.Oncotarget · 2017Pooled it
- Pharmacological activation of dopamine receptor D1 attenuates TGF-β-induced epithelial-mesenchymal transition in A549 and BEAS-2B cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Dopamine abrogates immunosuppression mediated by PD-L1 of cancer stem cells in a preclinical triple-negative breast cancer model.Acta pharmacologica Sinica · 2026Article
- Neurotransmitters in cancer: how receptor signaling and posttranslational modifications modulate tumor progression and offer new therapeutic targets.Cell communication and signaling : CCS · 2026Review
- The neuroimmune axis in breast cancer: from mechanistic insights to clinical applications.BMC medicine · 2026Review
- Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets.MedComm · 2025Review
- G Protein-Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers.MedComm · 2025Review
- Advances in the treatment of malignant tumors with neurological drugs.Discover oncology · 2025Review
- Expression Profiles of Dopamine-Related Genes and miRNAs Regulating Their Expression in Breast Cancer.International journal of molecular sciences · 2024Article
- DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC.Molecular oncology · 2024Article
- Proton Sensing GPCR's: The missing link to Warburg's Oncogenic Legacy?Journal of cancer biology · 2024Article
- Caveolin-1, a Determinant of the Fate of MCF-7 Breast Cancer Cells.Breast cancer : basic and clinical research · 2024Article
- Effects of Dopamine on stem cells and its potential roles in the treatment of inflammatory disorders: a narrative review.Stem cell research & therapy · 2023Review
- The tumor-nerve circuit in breast cancer.Cancer metastasis reviews · 2023Review
- Exploring neurotransmitters and their receptors for breast cancer prevention and treatment.Theranostics · 2023Review
- Dopamine receptor D3 is related to prognosis in human hepatocellular carcinoma and inhibits tumor growth.BMC cancer · 2022Article
- The Role of a Natural Amphibian Skin-Based Peptide, Ranatensin, in Pancreatic Cancers Expressing Dopamine D2 Receptors.Cancers · 2022Article
- DRD1 and DRD4 are differentially expressed in breast tumors and breast cancer stem cells: pharmacological implications.Translational cancer research · 2022Article
- Understanding the role of dopamine in cancer: past, present and future.Carcinogenesis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Patients with advanced breast cancer often fail to respond to treatment, creating a need to develop novel biomarkers and effective therapeutics. Dopamine (DA) is a catecholamine that binds to five G protein-coupled receptors. We discovered expression of DA type-1 receptors (D1Rs) in breast cancer, thereby identifying these receptors as novel therapeutic targets in this disease. Strong to moderate immunoreactive D1R expression was found in 30% of 751 primary breast carcinomas, and was associated with larger tumors, higher tumor grades, node metastasis and shorter patient survival. DA and D1R agonists, signaling through the cGMP/protein kinase G (PKG) pathway, suppressed cell viability, inhibited invasion and induced apoptosis in multiple breast cancer cell lines. Fenoldopam, a peripheral D1R agonist that does not penetrate the brain, dramatically suppressed tumor growth in two mouse models with D1R-expressing xenografts by increasing both necrosis and apoptosis. D1R-expressing primary tumors and metastases in mice were detected by fluorescence imaging. In conclusion, D1R overexpression is associated with advanced breast cancer and poor prognosis. Activation of the D1R/cGMP/PKG pathway induces apoptosis in vitro and causes tumor shrinkage in vivo. Fenoldopam, which is FDA (Food and Drug Administration) approved to treat renal hypertension, could be repurposed as a novel therapeutic agent for patients with D1R-expressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.